Relationship between periodontitis and subclinical risk indicators for chronic non-communicable diseases.

In view of the epidemiological relevance of periodontal disease and chronic noncommunicable diseases, the study aimed to evaluate the relationship between them through subclinical indicators of systemic risk in a population group with healthy habits, including alcohol and tobacco abstinence. A complete periodontal examination of six sites per tooth was performed in a sample of 420 participants from the Advento study (Sao Paulo), submitted to anthropometric and laboratory evaluation. Periodontitis was defined and classified based on the Community Periodontal Index score 3 (periodontal pocket = 4-5 mm) and score 4 (periodontal pocket ≥ 6 mm). The prevalence of mild/moderate and severe periodontitis was 20% and 8.2%, respectively. Both categories of periodontal disease had significantly higher levels of triglycerides, C-reactive protein, calcium score, and calcium percentile, whereas blood glucose after tolerance test was significantly higher among people with severe periodontitis and HDL-c levels were lower (p < 0.05). Young adults with severe periodontitis had significantly higher prevalence of obesity, pre-diabetes, hypertension, and metabolic syndrome. Besides these conditions, the older adults with severe periodontitis had significantly higher prevalence of dyslipidemia and subclinical atherosclerosis. The group with periodontitis had also a higher coronary heart disease risk based on the PROCAM score (p < 0.05). The results indicated associations of periodontitis with several systemic indicators for chronic noncommunicable diseases, and highlighted the need for multiprofessional measures in the whole care of patients.

Relationship between periodontitis and subclinical risk indicators for chronic non-communicable diseases

Abstract In view of the epidemiological relevance of periodontal disease and chronic noncommunicable diseases, the study aimed to evaluate the relationship between them through subclinical indicators of systemic risk in a population group with healthy habits, including alcohol and tobacco abstinence. A complete periodontal examination of six sites per tooth was performed in a sample of 420 participants from the Advento study (Sao Paulo), submitted to anthropometric and laboratory evaluation. Periodontitis was defined and classified based on the Community Periodontal Index score 3 (periodontal pocket = 4-5 mm) and score 4 (periodontal pocket ≥ 6 mm). The prevalence of mild/moderate and severe periodontitis was 20% and 8.2%, respectively. Both categories of periodontal disease had significantly higher levels of triglycerides, C-reactive protein, calcium score, and calcium percentile, whereas blood glucose after tolerance test was significantly higher among people with severe periodontitis and HDL-c levels were lower (p < 0.05). Young adults with severe periodontitis had significantly higher prevalence of obesity, pre-diabetes, hypertension, and metabolic syndrome. Besides these conditions, the older adults with severe periodontitis had significantly higher prevalence of dyslipidemia and subclinical atherosclerosis. The group with periodontitis had also a higher coronary heart disease risk based on the PROCAM score (p < 0.05). The results indicated associations of periodontitis with several systemic indicators for chronic noncommunicable diseases, and highlighted the need for multiprofessional measures in the whole care of patients.

Perda de inserção periodontal e associações com indicadores de risco sociodemográficos e comportamentais / Periodontal attachment loss and associations with sociodemographic and behavioral risk indicators

Resumo Introdução A perda de inserção clínica periodontal (PIP) tem sido indicada como parâmetro determinante para o estudo de indicadores de risco de periodontite crônica. Objetivo Descrever a prevalência, severidade e extensão de PIP em um grupo populacional que se abstém de álcool e tabaco, além de avaliar associações com características sociodemográficas e comportamentais dos participantes. Método Uma amostra de 420 indivíduos adultos, participantes do Estudo Advento (São Paulo), foi submetida ao exame periodontal de seis sítios por dente e respondeu um questionário estruturado. As associações foram verificadas por meio de análise de regressão logística múltipla. Resultado A prevalência de periodontite foi de 20,7% e de gengivite, 38,8%; a PIP média foi de 1,38 mm (± 0,5) e a perda dental, 5,4 (± 9,0). A prevalência de PIP ≥ 3 mm, ≥ 4 mm e ≥ 6 mm foi de 69,7%, 31,7% e 9,6% dos indivíduos, e 11,4%, 4,4% e 1,2% dos dentes por indivíduo, respectivamente. Houve associação significativa de PIP ≥ 4 mm com sexo masculino, idade superior a 55 anos, baixa escolaridade, placa visível, autocuidado irregular, falta de orientação em higiene bucal e doença sistêmica referida. Para PIP ≥ 6 mm, foi observada maior razão de chances para as variáveis idade e doença sistêmica. Conclusão O grupo populacional estudado apresentou baixa extensão e severidade de PIP, possivelmente pelas características da amostra. As associações de risco encontradas confirmam a necessidade de atenção integral ao paciente, incluindo o incentivo à prevenção e ao controle de doenças crônicas, ao lado de orientações específicas para higiene bucal.

Abstract Introduction Clinical attachment loss (CAL) has been indicated as a determining parameter for the study of risk indicators of chronic periodontitis. Objective To describe the prevalence, severity and extent of CAL in a population group that abstains from alcohol and tobacco use and to evaluate associations with sociodemographic and behavioral characteristics of participants. Method A sample of 420 adult individuals, participants of the Advento Study (São Paulo) were submitted to a periodontal examination of six sites per tooth and answered a structured questionnaire. Associations were verified by multiple logistic regression analysis. Result Prevalence of periodontitis was 20.7% and gingivitis 38.8%; mean CAL was 1.38mm (±0.5) and dental loss 5.4 (±9.0). Prevalence of CAL ≥3 mm, ≥4 mm and ≥6 mm was 69.7%, 31.7% and 9.6% of the individuals, affecting 11.4%, 4.4% and 1.2% of the teeth per individual, respectively. After adjustments, there was a significant association of CAL ≥4 mm with males, over 55 years of age, low education, visible plaque, irregular self-care, lack of oral hygiene guidance and reported systemic disease. For CAL ≥6 mm, there was a higher odds ratio for the variables age group and systemic disease. Conclusion The population group studied presented low extension and severity of CAL, possibly due to the sample characteristics. The risk associations found confirm the need for comprehensive patient care, including encouraging prevention and control of chronic diseases, along with specific oral hygiene guidelines.

Presença de lactose em medicamentos isentos de prescrição / Presence of lactose in nonprescription drugs

Introdução: a polifarmácia e a automedicação estão presentes na população brasileira, sendo frequente sua ocorrência com medicamentos isentos de prescrição. Ademais, a lactose é utilizada como excipiente em formas farmacêuticas sólidas. Objetivo: o presente estudo constitui uma pesquisa sobre lactose, na condição de excipiente, em medicamentos isentos de prescrição (MIPs). Metodologia: em 391 MIPs presentes em cinco formas farmacêuticas sólidas e analisadas por classes, categorias e marcas, foram coletadas, nos meses de abril e maio de 2018, informações quanto à presença de lactose em bulas disponíveis nos sites da Agência Nacional de Vigilância Sanitária e da indústria farmacêutica no Brasil. Resultados: constatou-se que a lactose está presente em 43,48% dos MIPs, sendo mais frequente nos comprimidos e comprimidos revestidos, nas proporções de 42,94% e 36,47%, respectivamente. Ela foi encontrada, predominantemente, em medicamentos similares, principalmente antialérgicos, analgésicos não opioides e anti-inflamatórios não esteroides, bem como na totalidade dos antidiarreicos e laxantes. Das 88 marcas analisadas, 30 apresentaram mais de 50% dos produtos com lactose. Identificou-se um percentual expressivo de medicamentos utilizados no controle dos sintomas de intolerância à lactose que continham esse carboidrato como excipiente. Conclusão: nas formas farmacêuticas analisadas, a presença de lactose nos MIPs é superior a 40%. A lactose presente pode ser agravante de sintomas gastrintestinais. Portanto, é essencial incluir, na embalagem dos medicamentos, a frase de alerta sobre a presença desse açúcar, visando à sua ampla divulgação, particularmente dirigida aos indivíduos com restrição de uso dessa substância.

Introduction: polypharmacy and self-medication are present in Brazilian population, frequently occurring for prescription-free medicines. In addition, lactose is used as an excipient in solid dosage forms of prescription-free medicines. Objective: the present study constitutes a research on lactose, as an excipient, in prescription-free medicines (MIPs). Methodology: in 391 MIPs present in five solid dosage pharmaceutical forms and analyzed by classes, categories and brands, in April and May 2018, information was collected on the presence of lactose in the package inserts available on the websites of the National Sanitary Surveillance Agency and on the pharmaceutical industry websites in Brazil. Results: it was found that lactose is present in 43.48% of the MIPs, being more frequent in tablets and coated tablets, in the proportions of 42.94% and 36.47%, respectively. It has been found predominantly in similar drugs, mainly antiallergics, non-opioid analgesics and non-steroidal anti-inflammatory drugs, as well as in all antidiarrheals and laxatives. Of the 88 brands analyzed, 30 presented over 50% of lactose products. An expressive percentage of drugs used to control the symptoms of lactose intolerance that contained this carbohydrate as an excipient were identified. Conclusion: in the pharmaceutical forms analyzed, the presence of lactose in the MIPs is higher than 40%. The lactose present may be aggravating gastrointestinal symptoms. It is therefore essential to include a warning on the presence of this sugar on the packaging of medicinal products, with a view to their wide dissemination, particularly for those who have a restricted use of that substance.